Republic of Korea

Population 2018  51 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>34 (31–36)</td>
<td>66 (61–71)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.32 (0.18–0.51)</td>
<td>0.63 (0.36–0.99)</td>
</tr>
<tr>
<td>MDR-RR-TB incidenceºº</td>
<td>1.5 (1.3–1.7)</td>
<td>2.9 (2.6–3.3)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>2.4 (2.3–2.5)</td>
<td>4.7 (4.4–4.9)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.035 (0.014–0.065)</td>
<td>0.07 (0.03–0.13)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases  3.2% (2.9–3.5)
Previously treated cases  9.2% (8.2–10)

TB case notifications, 2018

31 534
- % tested with rapid diagnostics at time of diagnosis  26%
- % with known HIV status  80%
- % pulmonary  78%
- % children aged 0–14 years  <1%
- % women  40%
- % men  60%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018  94% (87–100)

TB patients facing catastrophic total costs

7% (7–8)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive
- % on antiretroviral therapy  85%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- % New cases  85%
- % Previously treated cases  82%

Laboratory-confirmed cases*  MDR/RR-TB: 785, XDR-TB: 29

Patients started on treatment* **  MDR/RR-TB: 794, XDR-TB: 29

MDR/RR-TB cases tested for resistance to second-line drugs  738

Treatment success rate and cohort size

New and relapse cases registered in 2017  83%  31 699
Previously treated cases, excluding relapse, registered in 2017  68%  2 919
MDR/RR-TB cases started on second-line treatment in 2016  66%  852
XDR-TB cases started on second-line treatment in 2016  58%  36

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment  60% (45–93)

TB financing, 2019

National TB budget (US$ millions)  55

Funding source: 100% domestic, international, 0% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-18 Data: www.who.int/tb/data